In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 71, Issue 8, 2016, Pages 1103-1134

  Mayorga, C ^a   Celik, G ^b   Rouzaire, P ^c   Whitaker, P ^d   Bonadonna, P ^e   Rodrigues Cernadas, J ^f   Vultaggio, A ^g   Brockow, K ^h   Caubet, J C ⁱ   Makowska, J ^j   Nakonechna, A ^k   Romano, A ^l   Montanez M I ^m   Laguna, J J ⁿ   Zanoni, G ^o   Gueant, J L ^p   Oude Elberink, H ^q   Fernandez, J ^r   Viel, S ^s   Demoly, P ^t   Torres, M J ^a   more..

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b ANKARA UNIVERSITY   (Turkey)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITAL OF VERONA   (Italy)

^f Universidade do Porto   (Portugal)

^g CAREGGI UNIVERSITY HOSPITAL   (Italy)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^j MEDICAL UNIVERSITY OF LODZ   (Poland)

^k ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^l OASI RESEARCH INSTITUTE IRCCS   (Italy)

^m Institute of Biomedical Research in Malaga and BIONAND Nanomedicine Platform   (Spain)

ⁿ HOSPITAL CENTRAL DE LA CRUZ ROJA   (Spain)

^o UNIVERSITY OF VERONA   (Italy)

^p UNIVERSITY HOSPITAL OF NANCY   (France)

^q UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^r HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^s CENTRE HOSPITALIER LYON SUD   (France)

^t HÔPITAL ARNAUD DE VILLENEUVE   (France)

more..

Author keywords

diagnosis; drug hypersensitivity; IgE; in vitro; T cells

Indexed keywords

ARACHIDONIC ACID; BIOLOGICAL PRODUCT; CELL MARKER; CYTOKINE; HISTAMINE; IMMUNOGLOBULIN E; TRYPTASE; BIOLOGICAL MARKER; HLA ANTIGEN;

ALLELE; ALLERGY RAPID TEST; ALLERGY TEST; ANTIBODY DETECTION; ARTICLE; BASOPHIL; BASOPHIL ACTIVATION TEST; BLOOD; CELL ACTIVATION; CONSENSUS; CYTOKINE RELEASE; DISEASE CLASSIFICATION; DRUG HYPERSENSITIVITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HLA SYSTEM; HUMAN; IMMUNOASSAY; IN VITRO STUDY; LYMPHOCYTE TRANSFORMATION TEST; MEDIATOR RELEASE; NONALLERGIC DRUG HYPERSENSITIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SKIN BIOPSY; SYSTEMATIC REVIEW; T LYMPHOCYTE; GENETICS; IMMUNITY; IMMUNOLOGY; META ANALYSIS; METABOLISM; PROCEDURES; SKIN TEST;

BIOMARKERS; DRUG HYPERSENSITIVITY; HLA ANTIGENS; HUMANS; IMMUNITY; IMMUNOGLOBULIN E; IN VITRO TECHNIQUES; PRACTICE GUIDELINES AS TOPIC; SKIN TESTS; T-LYMPHOCYTES;

EID: 84971425607     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12886     Document Type: Article

References (185)

1. Demoly P, Kropf R, Bircher A, Pichler WJ. Drug hypersensitivity: questionnaire. EAACI interest group on drug hypersensitivity. Allergy 1999;54:999–1003.
2. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002;57:45–51.
3. Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB et al. Skin test concentrations for systemically administered drugs – an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013;68:702–712.
4. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003;58:854–863.
5. Romano A, Torres MJ, Castells M, Sanz ML, Blanca M. Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol 2011;127(3 Suppl):S67–S73.
6. Torres MJ, Blanca M, Fernandez J, Romano A, Weck A, Aberer W et al. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy 2003;58:961–972.
7. Blanca M, Romano A, Torres MJ, Fernandez J, Mayorga C, Rodriguez J et al. Update on the evaluation of hypersensitivity reactions to betalactams. Allergy 2009;64:183–193.
8. Brockow K, Romano A, Aberer W, Bircher AJ, Barbaud A, Bonadonna P et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy 2009;64:234–241.
9. Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 2013;68:1219–1232.
10. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA et al. International Consensus on drug allergy. Allergy 2014;69:420–437.
11. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323:334–336.
12. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004;113:832–836.
13. Coombs PRGP. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell RR, editor. Clinical Aspects of Immunology. Oxford: Oxford Univ Pr; 1968: 575–596.
14. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003;139:683–693.
15. Romano A, Blanca M, Torres MJ, Bircher A, Aberer W, Brockow K et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy 2004;59:1153–1160.
16. Sanz ML, Gamboa PM, Garcia-Figueroa BE, Ferrer M. In vitro diagnosis of anaphylaxis. Chem Immunol Allergy 2010;95:125–140.
17. Vitte J. Human mast cell tryptase in biology and medicine. Mol Immunol 2015;63:18–24.
18. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006;26:451–463.
19. Berroa F, Lafuente A, Javaloyes G, Ferrer M, Moncada R, Goikoetxea MJ et al. The usefulness of plasma histamine and different tryptase cut-off points in the diagnosis of peranaesthetic hypersensitivity reactions. Clin Exp Allergy 2014;44:270–277.
20. Dybendal T, Guttormsen AB, Elsayed S, Askeland B, Harboe T, Florvaag E. Screening for mast cell tryptase and serum IgE antibodies in 18 patients with anaphylactic shock during general anaesthesia. Acta Anaesthesiol Scand 2003;47:1211–1218.
21. Schwartz LB, Min HK, Ren S, Xia HZ, Hu J, Zhao W et al. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells. J Immunol 2003;170:5667–5673.
22. Schwartz LB, Yunginger JW, Miller J, Bokhari R, Dull D. Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest 1989;83:1551–1555.
23. Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012;157:215–225.
24. Enrique E, Garcia-Ortega P, Sotorra O, Gaig P, Richart C. Usefulness of UniCAP-Tryptase fluoroimmunoassay in the diagnosis of anaphylaxis. Allergy 1999;54:602–606.
25. Lin RY, Schwartz LB, Curry A, Pesola GR, Knight RJ, Lee HS et al. Histamine and tryptase levels in patients with acute allergic reactions: an emergency department-based study. J Allergy Clin Immunol 2000;106(1 Pt 1):65–71.
26. Stone SF, Cotterell C, Isbister GK, Holdgate A, Brown SG. Emergency Department Anaphylaxis I. Elevated serum cytokines during human anaphylaxis: identification of potential mediators of acute allergic reactions. J Allergy Clin Immunol 2009;124:786–792.
27. Sala-Cunill A, Cardona V, Labrador-Horrillo M, Luengo O, Esteso O, Garriga T et al. Usefulness and limitations of sequential serum tryptase for the diagnosis of anaphylaxis in 102 patients. Int Arch Allergy Immunol 2013;160:192–199.
28. Komericki P, Arbab E, Grims R, Kranke B, Aberer W. Tryptase as severity marker in drug provocation tests. Int Arch Allergy Immunol 2006;140:164–169.
29. Keyzer JJ, de MJ, van Doormaal JJ, van Voorst Vader PC. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med 1983;309:1603–1605.
30. Laroche D, Gomis P, Gallimidi E, Malinovsky JM, Mertes PM. Diagnostic value of histamine and tryptase concentrations in severe anaphylaxis with shock or cardiac arrest during anesthesia. Anesthesiology 2014;121:272–279.
31. Gueant JL, Aimone-Gastin I, Namour F, Laroche D, Bellou A, Laxenaire MC. Diagnosis and pathogenesis of the anaphylactic and anaphylactoid reactions to anaesthetics. Clin Exp Allergy 1998;28(Suppl 4):65–70.
32. Keyzer JJ, van Saene HK, van den Berg GA, Wolthers BG. Influence of decontamination of the digestive tract on the urinary excretion of histamine and some of its metabolites. Agents Actions 1984;15:238–241.
33. Keyzer JJ, Breukelman H, Wolthers BG, van den Heuvel M, Kromme N, Berg WC. Urinary excretion of histamine and some of its metabolites in man: influence of the diet. Agents Actions 1984;15:189–194.
34. Hon YY, Jusko WJ, Zhou HH, Chen GL, Guo D, Zhou G et al. Endogenous histamine and cortisol levels in subjects with different histamine N-methyltransferase C314T genotypes: a pilot study. Mol Diagn Ther 2006;10:109–114.
35. Laroche D, Aimone-Gastin I, Dubois F, Huet H, Gerard P, Vergnaud MC et al. Mechanisms of severe, immediate reactions to iodinated contrast material. Radiology 1998;209:183–190.
36. Mertes PM, Laxenaire MC, Alla F. Groupe d'Etudes des Reactions Anaphylactoides P. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology 2003;99:536–545.
37. Hammar E, Berglund A, Hedin A, Norrman A, Rustas K, Ytterstrom U et al. An immunoassay for histamine based on monoclonal antibodies. J Immunol Methods 1990;128:51–58.
38. Hari Y, Frutig-Schnyder K, Hurni M, Yawalkar N, Zanni MP, Schnyder B et al. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy 2001;31:1398–1408.
39. Pichler WJ, Yawalkar N, Britschgi M, Depta J, Strasser I, Schmid S et al. Cellular and molecular pathophysiology of cutaneous drug reactions. Am J Clin Dermatol 2002;3:229–238.
40. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)–a clinical reaction pattern. J Cutan Pathol 2001;28:113–119.
41. Halevy S. Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol 2009;9:322–328.
42. Paulmann M, Mockenhaupt M. Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. J Dtsch Dermatol Ges 2015;13:625–645.
43. Wu Y, Farrell J, Pirmohamed M, Park BK, Naisbitt DJ. Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol 2007;119:973–981.
44. Yawalkar N, Shrikhande M, Hari Y, Nievergelt H, Braathen LR, Pichler WJ. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000;106:1171–1176.
45. Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004;114:1209–1215.
46. Rzany B, Hering O, Mockenhaupt M, Schroder W, Goerttler E, Ring J et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 1996;135:6–11.
47. Fernandez TD, Canto G, Blanca M. Molecular mechanisms of maculopapular exanthema. Curr Opin Infect Dis 2009;22:272–278.
48. Mayorga C, Pena RR, Blanca-Lopez N, Lopez S, Martin E, Torres MJ. Monitoring the acute phase response in non-immediate allergic drug reactions. Curr Opin Allergy Clin Immunol 2006;6:249–257.
49. Torres MJ, Mayorga C, Fernandez TD, Cornejo-Garcia JA, Antunez C, Valenzuela M et al. T cell assessment in allergic drug reactions during the acute phase according to the time of occurrence. Int J Immunopathol Pharmacol 2006;19:119–130.
50. Blanca M, Posadas S, Torres MJ, Leyva L, Mayorga C, Gonzalez L et al. Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with nonimmediate cutaneous allergic drug reactions. Allergy 2000;55:998–1004.
51. Fernandez TD, Mayorga C, Torres MJ, Cornejo-Garcia JA, Lopez S, Chaves P et al. Cytokine and chemokine expression in the skin from patients with maculopapular exanthema to drugs. Allergy 2008;63:712–719.
52. Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002;8:157–165.
53. Posadas SJ, Leyva L, Torres MJ, Rodriguez JL, Bravo I, Rosal M et al. Subjects with allergic reactions to drugs show in vivo polarized patterns of cytokine expression depending on the chronology of the clinical reaction. J Allergy Clin Immunol 2000;106:769–776.
54. Cornejo-Garcia JA, Fernandez TD, Torres MJ, Carballo M, Hernan I, Antunez C et al. Differential cytokine and transcription factor expression in patients with allergic reactions to drugs. Allergy 2007;62:1429–1438.
55. Cho YT, Lin JW, Chen YC, Chang CY, Hsiao CH, Chung WH et al. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol 2014;70:539–548.
56. Tapia B, Padial A, Sanchez-Sabate E, Alvarez-Ferreira J, Morel E, Blanca M et al. Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions. J Allergy Clin Immunol 2004;114:335–340.
57. Ebo DG, Leysen J, Mayorga C, Rozieres A, Knol EF, Terreehorst I. The in vitro diagnosis of drug allergy: status and perspectives. Allergy 2011;66:1275–1286.
58. Garcia JJ, Blanca M, Moreno F, Vega JM, Mayorga C, Fernandez J et al. Determination of IgE antibodies to the benzylpenicilloyl determinant: a comparison of the sensitivity and specificity of three radio allergo sorbent test methods. J Clin Lab Anal 1997;11:251–257.
59. Montanez MI, Perez-Inestrosa E, Suau R, Mayorga C, Torres MJ, Blanca M. Dendrimerized cellulose as a scaffold for artificial antigens with applications in drug allergy diagnosis. Biomacromolecules 2008;9:1461–1466.
60. Romano A, Gueant-Rodriguez RM, Viola M, Amoghly F, Gaeta F, Nicolas JP et al. Diagnosing immediate reactions to cephalosporins. Clin Exp Allergy 2005;35:1234–1242.
61. Manfredi M, Severino M, Testi S, Macchia D, Ermini G, Pichler WJ et al. Detection of specific IgE to quinolones. J Allergy Clin Immunol 2004;113:155–160.
62. Aranda A, Mayorga C, Ariza A, Dona I, Rosado A, Blanca-Lopez N et al. In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones. Allergy 2011;66:247–254.
63. Ruiz-Sanchez AJ, Montanez MI, Mayorga C, Torres MJ, Kehr NS, Vida Y et al. Dendrimer-modified solid supports: nanostructured materials with potential drug allergy diagnostic applications. Curr Med Chem 2012;19:4942–4954.
64. Fontaine C, Mayorga C, Bousquet PJ, Arnoux B, Torres MJ, Blanca M et al. Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy. Allergy 2007;62:47–52.
65. Blanca M, Mayorga C, Torres MJ, Reche M, Moya MC, Rodriguez JL et al. Clinical evaluation of Pharmacia CAP System RAST FEIA amoxicilloyl and benzylpenicilloyl in patients with penicillin allergy. Allergy 2001;56:862–870.
66. Torres MJ, Romano A, Mayorga C, Moya MC, Guzman AE, Reche M et al. Diagnostic evaluation of a large group of patients with immediate allergy to penicillins: the role of skin testing. Allergy 2001;56:850–856.
67. Sanz ML, Gamboa PM, Antepara I, Uasuf C, Vila L, Garcia-Aviles C et al. Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics. Clin Exp Allergy 2002;32:277–286.
68. Rouzaire P, Proton G, Bienvenu F, Guilloux L, Benoit Y, Piriou V et al. IgE antibody detection in the diagnosis of hypersensitivity to neuromuscular blocking agents. Acta Anaesthesiol Scand 2012;56:263–264.
69. Laroche D, Chollet-Martin S, Leturgie P, Malzac L, Vergnaud MC, Neukirch C et al. Evaluation of a new routine diagnostic test for immunoglobulin e sensitization to neuromuscular blocking agents. Anesthesiology 2011;114:91–97.
70. Ebo DG, Bridts CH, Hagendorens MM, Mertens CH, De Clerck LS, Stevens WJ. Flow-assisted diagnostic management of anaphylaxis from rocuronium bromide. Allergy 2006;61:935–939.
71. Garvey LH, Kroigaard M, Poulsen LK, Skov PS, Mosbech H, Venemalm L et al. IgE-mediated allergy to chlorhexidine. J Allergy Clin Immunol 2007;120:409–415.
72. Johansson SG, Adedoyin J, van Hage M, Gronneberg R, Nopp A. False-positive penicillin immunoassay: an unnoticed common problem. J Allergy Clin Immunol 2013;132:235–237.
73. Romano A, Mayorga C, Torres MJ, Artesani MC, Suau R, Sanchez F et al. Immediate allergic reactions to cephalosporins: cross-reactivity and selective responses. J Allergy Clin Immunol 2000;106:1177–1183.
74. Antunez C, Blanca-Lopez N, Torres MJ, Mayorga C, Perez-Inestrosa E, Montanez MI et al. Immediate allergic reactions to cephalosporins: evaluation of cross-reactivity with a panel of penicillins and cephalosporins. J Allergy Clin Immunol 2006;117:404–410.
75. Guilloux L, Ricard-Blum S, Ville G, Motin J. A new radioimmunoassay using a commercially available solid support for the detection of IgE antibodies against muscle relaxants. J Allergy Clin Immunol 1992;90:153–159.
76. Gueant JL, Mata E, Monin B, Moneret-Vautrin DA, Kamel L, Nicolas JP et al. Evaluation of a new reactive solid phase for radioimmunoassay of serum specific IgE against muscle relaxant drugs. Allergy 1991;46:452–458.
77. Gueant JL, Mata E, Masson C, Gerard P, Moneret-Vautrin DA, Mouton-Faivre C et al. Non-specific cross-reactivity of hydrophobic serum IgE to hydrophobic drugs. Mol Immunol 1995;32:259–266.
78. Himly M, Jahn-Schmid B, Pittertschatscher K, Bohle B, Grubmayr K, Ferreira F et al. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J Allergy Clin Immunol 2003;111:882–888.
79. Harrer A, Lang R, Grims R, Braitsch M, Hawranek T, Aberer W et al. Diclofenac hypersensitivity: antibody responses to the parent drug and relevant metabolites. PLoS One 2010;5:e13707.
80. Fernandez TD, Torres MJ, Blanca-Lopez N, Rodriguez-Bada JL, Gomez E, Canto G et al. Negativization rates of IgE radioimmunoassay and basophil activation test in immediate reactions to penicillins. Allergy 2009;64:242–248.
81. Vultaggio A, Matucci A, Virgili G, Rossi O, Fili L, Parronchi P et al. Influence of total serum IgE levels on the in vitro detection of beta-lactams-specific IgE antibodies. Clin Exp Allergy 2009;39:838–844.
82. Vultaggio A, Virgili G, Gaeta F, Romano A, Maggi E, Matucci A. High Serum beta-Lactams Specific/Total IgE Ratio Is Associated with Immediate Reactions to beta-Lactams Antibiotics. PLoS One 2015;10:e0121857.
83. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008;358:1109–1117.
84. Mariotte D, Dupont B, Gervais R, Galais MP, Laroche D, Tranchant A et al. Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis. MAbs 2011;3:396–401.
85. Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010;65:657–661.
86. Matucci A, Pratesi S, Petroni G, Nencini F, Virgili G, Milla M et al. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy 2013;43:659–664.
87. Vultaggio A, Matucci A, Nencini F, Pratesi S, Petroni G, Cammelli D et al. Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab. Int Arch Allergy Immunol 2012;159:321–326.
88. Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleypen J. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 2010;32:1597–1609.
89. Munoz-Cano R, Carnes J, Sanchez-Lopez J, Saiz A, Bartra J, Lopez-Matas MA et al. Biological agents: new drugs, old problems. J Allergy Clin Immunol 2010;126:394–395.
90. Georgitis JW, Browning MC, Steiner D, Lorentz WB. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection. Ann Allergy 1991;66:343–347.
91. Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol 2011;11:262–268.
92. De Week AL, Sanz ML, Gamboa PM, Aberer W, Sturm G, Bilo MB et al. Diagnosis of immediate-type beta-lactam allergy in vitro by flow-cytometric basophil activation test and sulfidoleukotriene production: a multicenter study. J Investig Allergol Clin Immunol 2009;19:91–109.
93. Demoly P, Lebel B, Messaad D, Sahla H, Rongier M, Daures JP et al. Predictive capacity of histamine release for the diagnosis of drug allergy. Allergy 1999;54:500–506.
94. Mata E, Gueant JL, Moneret-Vautrin DA, Bermejo N, Gerard P, Nicolas JP et al. Clinical evaluation of in vitro leukocyte histamine release in allergy to muscle relaxant drugs. Allergy 1992;47:471–476.
95. Garcia-Aviles C, Sanz ML, Gamboa PM, Urrutia I, Antepara I, Jauregui I et al. Antigen specific quantification of sulfidoleukotrienes in patients allergic to Betalactam antibiotics. J Investig Allergol Clin Immunol 2005;15:37–45.
96. Gamboa PM, Garcia-Aviles MC, Urrutia I, Antepara I, Esparza R, Sanz ML. Basophil activation and sulfidoleukotriene production in patients with immediate allergy to betalactam antibiotics and negative skin tests. J Investig Allergol Clin Immunol 2004;14:278–283.
97. Torres MJ, Padial A, Mayorga C, Fernandez T, Sanchez-Sabate E, Cornejo-Garcia JA et al. The diagnostic interpretation of basophil activation test in immediate allergic reactions to betalactams. Clin Exp Allergy 2004;34:1768–1775.
98. Torres MJ, Ariza A, Mayorga C, Dona I, Blanca-Lopez N, Rondon C et al. Clavulanic acid can be the component in amoxicillin-clavulanic acid responsible for immediate hypersensitivity reactions. J Allergy Clin Immunol 2010;125:502–505.
99. Longo N, Gamboa PM, Gastaminza G, Audicana MT, Antepara I, Jauregui I et al. Diagnosis of clavulanic acid allergy using basophil activation and leukotriene release by basophils. J Investig Allergol Clin Immunol 2008;18:473–475.
100. Abuaf N, Rajoely B, Ghazouani E, Levy DA, Pecquet C, Chabane H et al. Validation of a flow cytometric assay detecting in vitro basophil activation for the diagnosis of muscle relaxant allergy. J Allergy Clin Immunol 1999;104(2 Pt 1):411–418.
101. Kvedariene V, Kamey S, Ryckwaert Y, Rongier M, Bousquet J, Demoly P et al. Diagnosis of neuromuscular blocking agent hypersensitivity reactions using cytofluorimetric analysis of basophils. Allergy 2006;61:311–315.
102. Sudheer PS, Hall JE, Read GF, Rowbottom AW, Williams PE. Flow cytometric investigation of peri-anaesthetic anaphylaxis using CD63 and CD203c. Anaesthesia 2005;60:251–256.
103. Monneret G, Benoit Y, Debard AL, Gutowski MC, Topenot I, Bienvenu J. Monitoring of basophil activation using CD63 and CCR3 in allergy to muscle relaxant drugs. Clin Immunol 2002;102:192–199.
104. Hagau N, Gherman-Ionica N, Sfichi M, Petrisor C. Threshold for basophil activation test positivity in neuromuscular blocking agents hypersensitivity reactions. Allergy Asthma Clin Immunol 2013;9:42.
105. Uyttebroek AP, Sabato V, Leysen J, Bridts CH, De Clerck LS, Ebo DG. Flowcytometric diagnosis of atracurium-induced anaphylaxis. Allergy 2014;69:1324–1332.
106. Gamboa PM, Sanz ML, Caballero MR, Antepara I, Urrutia I, Jauregui I et al. Use of CD63 expression as a marker of in vitro basophil activation and leukotriene determination in metamizol allergic patients. Allergy 2003;58:312–317.
107. Gomez E, Blanca-Lopez N, Torres MJ, Requena G, Rondon C, Canto G et al. Immunoglobulin E-mediated immediate allergic reactions to dipyrone: value of basophil activation test in the identification of patients. Clin Exp Allergy 2009;39:1217–1224.
108. Ben Said B, Berard F, Bienvenu J, Nicolas JF, Rozieres A. Usefulness of basophil activation tests for the diagnosis of IgE-mediated allergy to quinolones. Allergy 2010;65:535–536.
109. Blanca-Lopez N, Ariza A, Dona I, Mayorga C, Montanez MI, Garcia-Campos J et al. Hypersensitivity reactions to fluoroquinolones: analysis of the factors involved. Clin Exp Allergy 2013;43:560–567.
110. Rouzaire P, Nosbaum A, Denis L, Bienvenu F, Berard F, Cozon G et al. Negativity of the basophil activation test in quinolone hypersensitivity: a breakthrough for provocation test decision-making. Int Arch Allergy Immunol 2012;157:299–302.
111. Pinnobphun P, Buranapraditkun S, Kampitak T, Hirankarn N, Klaewsongkram J. The diagnostic value of basophil activation test in patients with an immediate hypersensitivity reaction to radiocontrast media. Ann Allergy Asthma Immunol 2011;106:387–393.
112. Salas M, Gomez F, Fernandez TD, Dona I, Aranda A, Ariza A et al. Diagnosis of immediate hypersensitivity reactions to radiocontrast media. Allergy 2013;68:1203–1206.
113. Hoffmann HJ, Santos AF, Mayorga C, Nopp A, Eberlein B, Ferrer M et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy 2015;70:1393–1405.
114. Mayorga C, Andreu I, Aranda A, Dona I, Montanez MI, Blanca-Lopez N et al. Fluoroquinolone photodegradation influences specific basophil activation. Int Arch Allergy Immunol 2013;160:377–382.
115. Sousa-Pinto B, Pinto-Ramos J, Correia C, Goncalves-Costa G, Gomes L, Gil-Mata S et al. Pharmacogenetics of abacavir hypersensitivity: a systematic review and meta-analysis of the association with HLA-B*57:01. J Allergy Clin Immunol 2015;136:1092–1094.
116. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568–579.
117. Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 2011;127(3 Suppl):S60–S66.
118. Colombo S, Rauch A, Rotger M, Fellay J, Martinez R, Fux C et al. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J Infect Dis 2008;198:864–867.
119. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.
120. Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008;49:2087–2091.
121. Mehta TY, Prajapati LM, Mittal B, Joshi CG, Sheth JJ, Patel DB et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009;75:579–582.
122. Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 2013;149:1025–1032.
123. Niihara H, Kakamu T, Fujita Y, Kaneko S, Morita E. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol 2012;39:594–601.
124. Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J 2014;14:281–288.
125. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102:4134–4139.
126. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18:99–107.
127. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008;9:1617–1622.
128. Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009;19:704–709.
129. Goncalo M, Coutinho I, Teixeira V, Gameiro AR, Brites MM, Nunes R et al. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population. Br J Dermatol 2013;169:660–665.
130. Kang HR, Jee YK, Kim YS, Lee CH, Jung JW, Kim SH et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011;21:303–307.
131. Pirmohamed M, Ostrov DA, Park BK. New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. J Allergy Clin Immunol 2015;136:236–244.
132. Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheumatol 2016;12:235–242.
133. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006;43:99–102.
134. Waters LJ, Mandalia S, Gazzard B, Nelson M. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. AIDS 2007;21:2533–2534.
135. Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007;45:1–3.
136. Research C for DE. Postmarket Drug Safety Information for Patients and Providers—Information for Healthcare Professionals: Dangerous or Even Fatal Skin Reactions—Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics) (Internet). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124718. htm. Accessed 3 May 2015.
137. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431–1446.
138. Schnyder B, Pichler WJ. Skin and laboratory tests in amoxicillin- and penicillin-induced morbilliform skin eruption. Clin Exp Allergy 2000;30:590–595.
139. Luque I, Leyva L, Jose Torres M, Rosal M, Mayorga C, Segura JM et al. In vitro T-cell responses to beta-lactam drugs in immediate and nonimmediate allergic reactions. Allergy 2001;56:611–618.
140. Rodriguez-Pena R, Lopez S, Mayorga C, Antunez C, Fernandez TD, Torres MJ et al. Potential involvement of dendritic cells in delayed-type hypersensitivity reactions to beta-lactams. J Allergy Clin Immunol 2006;118:949–956.
141. Khalil G, El-Sabban M, Al-Ghadban S, Azzi S, Shamra S, Khalife S et al. Cytokine expression profile of sensitized human T lymphocytes following in vitro stimulation with amoxicillin. Eur Cytokine Netw 2008;19:131–141.
142. Rozieres A, Hennino A, Rodet K, Gutowski MC, Gunera-Saad N, Berard F et al. Detection and quantification of drug-specific T cells in penicillin allergy. Allergy 2009;64:534–542.
143. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004;59:809–820.
144. Mayorga C, Sanz ML, Gamboa P, Garcia-Aviles MC, Fernandez J, Torres MJ et al. In vitro methods for diagnosing nonimmediate hypersensitivity reactions to drugs. J Investig Allergol Clin Immunol 2013;23:213–225.
145. Thong BY, Mirakian R, Castells M, Pichler W, Romano A, Bonadonna P et al. A world allergy organization international survey on diagnostic procedures and therapies in drug allergy/hypersensitivity. World Allergy Organ J 2011;4:257–270.
146. Porebski G, Pecaric-Petkovic T, Groux-Keller M, Bosak M, Kawabata TT, Pichler WJ. In vitro drug causality assessment in Stevens-Johnson syndrome - alternatives for lymphocyte transformation test. Clin Exp Allergy 2013;43:1027–1037.
147. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997;27:175–181.
148. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007;62:1439–1444.
149. Polak ME, Belgi G, McGuire C, Pickard C, Healy E, Friedmann PS et al. In vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions. Br J Dermatol 2013;168:539–549.
150. Lopez S, Torres MJ, Rodriguez-Pena R, Blanca-Lopez N, Fernandez TD, Antunez C et al. Lymphocyte proliferation response in patients with delayed hypersensitivity reactions to heparins. Br J Dermatol 2009;160:259–265.
151. Antunez C, Barbaud A, Gomez E, Audonnet S, Lopez S, Gueant-Rodriguez RM et al. Recognition of iodixanol by dendritic cells increases the cellular response in delayed allergic reactions to contrast media. Clin Exp Allergy 2011;41:657–664.
152. Gomez ECJ, Torres MJ, Blanca M, Mayorga C. Effect of metabolising cell system in lymphocyte transformation test to evaluate non immediate reactions to anticonvulsivants. In: EAACI Istanbul: EAACI; 2011.
153. Srinoulprasert Y, Pichler WJ. Enhancement of Drug-Specific Lymphocyte Proliferation Using CD25-Depleted CD3 Effector Cells. Int Arch Allergy Immunol 2014;163:198–205.
154. Zawodniak A, Lochmatter P, Yerly D, Kawabata T, Lerch M, Yawalkar N et al. In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases. Allergy 2010;65:376–384.
155. Jurado-Palomo J, Cabanas R, Prior N, Bobolea ID, Fiandor-Roman AM, Lopez-Serrano MC et al. Use of the lymphocyte transformation test in the diagnosis of DRESS syndrome induced by ceftriaxone and piperacillin-tazobactam: two case reports. J Investig Allergol Clin Immunol 2010;20:433–436.
156. Roujeau JC, Albengres E, Moritz S, Piacentino A, Cuny M, Revuz J et al. Lymphocyte transformation test in drug-induced toxic epidermal necrolysis. Int Arch Allergy Appl Immunol 1985;78:22–24.
157. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995;155:462–472.
158. Orasch CE, Helbling A, Zanni MP, Yawalkar N, Hari Y, Pichler WJ. T-cell reaction to local anaesthetics: relationship to angioedema and urticaria after subcutaneous application–patch testing and LTT in patients with adverse reaction to local anaesthetics. Clin Exp Allergy 1999;29:1549–1554.
159. Sachs B, Erdmann S. Malte Baron J, Neis M, al Masaoudi T, Merk HF. Determination of interleukin-5 secretion from drug-specific activated ex vivo peripheral blood mononuclear cells as a test system for the in vitro detection of drug sensitization. Clin Exp Allergy 2002;32:736–744.
160. Beeler A, Engler O, Gerber BO, Pichler WJ. Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J Allergy Clin Immunol 2006;117:455–462.
161. Suzuki Y, Miwa S, Shirai M, Ohba H, Murakami M, Fujita K et al. Drug lymphocyte stimulation test in the diagnosis of adverse reactions to antituberculosis drugs. Chest 2008;134:1027–1032.
162. Sullivan A, Gibson A, Park BK, Naisbitt DJ. Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions? Expert Opin Drug Metab Toxicol 2015;11:357–368.
163. Esser S, Jablonka R, Heinemann FM, Reuter S, Jaeger H, von Krosigk A et al. Detection of abacavir hypersensitivity by ELISpot method. Inflamm Allergy Drug Targets 2012;11:227–234.
164. Tanvarasethee B, Buranapraditkun S, Klaewsongkram J. The potential of using enzyme-linked immunospot to diagnose cephalosporin-induced maculopapular exanthems. Acta Derm Venereol 2013;93:66–69.
165. Fu M, Gao Y, Pan Y, Li W, Liao W, Wang G et al. Recovered patients with Stevens-Johson syndrome and toxic epidermal necrolysis maintain long-lived IFN-gamma and sFasL memory response. PLoS One 2012;7:e45516.
166. Beeler A, Zaccaria L, Kawabata T, Gerber BO, Pichler WJ. CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity. Allergy 2008;63:181–188.
167. Martin M, Wurpts G, Ott H, Baron JM, Erdmann S, Merk HF et al. In vitro detection and characterization of drug hypersensitivity using flow cytometry. Allergy 2010;65:32–39.
168. Lochmatter P, Beeler A, Kawabata TT, Gerber BO, Pichler WJ. Drug-specific in vitro release of IL-2, IL-5, IL-13 and IFN-gamma in patients with delayed-type drug hypersensitivity. Allergy 2009;64:1269–1278.
169. Halevy S, Grossman N. Multiple drug allergy in patients with cutaneous adverse drug reactions diagnosed by in vitro drug-induced interferon-gamma release. Isr Med Assoc J 2008;10:865–868.
170. Niwa Y, Akamatsu H, Sumi H, Ozaki Y, Abe A. Evidence for degradation of cytokines in the serum of patients with atopic dermatitis by calcium-dependent protease. Arch Dermatol Res 2000;292:391–396.
171. De Weck AL, Sanz ML, Gamboa PM, Aberer W, Blanca M, Correia S et al. Nonsteroidal anti-inflammatory drug hypersensitivity syndrome. A multicenter study. I. Clinical findings and in vitro diagnosis. J Investig Allergol Clin Immunol 2009;19:355–369.
172. Bavbek S, Dursun AB, Birben E, Kalayci O, Misirligil Z. Cellular allergen stimulation test with acetylsalicylic acid-lysine is not a useful test to discriminate between asthmatic patients with and without acetylsalicylic acid sensitivity. Int Arch Allergy Immunol 2009;149:58–64.
173. Lebel B, Messaad D, Kvedariene V, Rongier M, Bousquet J, Demoly P. Cysteinyl-leukotriene release test (CAST) in the diagnosis of immediate drug reactions. Allergy 2001;56:688–692.
174. May A, Weber A, Gall H, Kaufmann R, Zollner TM. Means of increasing sensitivity of an in vitro diagnostic test for aspirin intolerance. Clin Exp Allergy 1999;29:1402–1411.
175. Kowalski ML, Ptasinska A, Jedrzejczak M, Bienkiewicz B, Cieslak M, Grzegorczyk J et al. Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest). Allergy 2005;60:1139–1145.
176. Korosec P, Tisler U, Bajrovic N, Silar M, Mrhar A, Kosnik M. Acetylsalicylic acid-triggered 15-HETE generation by peripheral leukocytes for identifying ASA sensitivity. Respir Med 2011;105(Suppl 1):S81–S83.
177. Sanz ML, Gamboa P, de Weck AL. A new combined test with flowcytometric basophil activation and determination of sulfidoleukotrienes is useful for in vitro diagnosis of hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2005;136:58–72.
178. Gamboa P, Sanz ML, Caballero MR, Urrutia I, Antepara I, Esparza R et al. The flow-cytometric determination of basophil activation induced by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome. Clin Exp Allergy 2004;34:1448–1457.
179. Celik GE, Schroeder JT, Hamilton RG, Saini SS, Adkinson NF. Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease. Clin Exp Allergy 2009;39:1522–1531.
180. Bavbek S, Ikinciogullari A, Dursun AB, Guloglu D, Arikan M, Elhan AH et al. Upregulation of CD63 or CD203c alone or in combination is not sensitive in the diagnosis of nonsteroidal anti-inflammatory drug intolerance. Int Arch Allergy Immunol 2009;150:261–270.
181. Rodriguez-Trabado A, Camara-Hijon C, Ramos-Cantarino A, Porcel-Carreno SL, Jimenez-Timon S, Pereira-Navarro G et al. Basophil activation test for the in vitro diagnosis of nonsteroidal anti-inflammatory drug hypersensitivity. Allergy Asthma Proc 2008;29:241–249.
182. Korosec P, Mavsar N, Bajrovic N, Silar M, Mrhar A, Kosnik M. Basophil responsiveness and clinical picture of acetylsalicylic acid intolerance. Int Arch Allergy Immunol 2011;155:257–262.
183. Abuaf N, Rostane H, Barbara J, Toly-Ndour C, Gaouar H, Mathelier-Fusade P et al. Comparison of CD63 Upregulation Induced by NSAIDs on Basophils and Monocytes in Patients with NSAID Hypersensitivity. J Allergy (Cairo) 2012;2012:580873.
184. Wismol P, Putivoranat P, Buranapraditkun S, Pinnobphun P, Ruxrungtham K, Klaewsongkram J. The values of nasal provocation test and basophil activation test in the different patterns of ASA/NSAID hypersensitivity. Allergol Immunopathol (Madr) 2012;40:156–163.
185. Ariza A, Fernandez TD, Dona I, Aranda A, Blanca-Lopez N, Melendez L et al. Basophil activation after nonsteroidal anti-inflammatory drugs stimulation in patients with immediate hypersensitivity reactions to these drugs. Cytometry A 2014;85:400–407.